Ama-platelets awaphazanyiswa yi-Celebrex

Ama-Platelet awaphazamiseki ngisho nangama-dose anconywe izikhathi ezingu-6 ze-osteoarthritis

Lesi sihloko siyingxenye ye- Arthritis Archives.

Idatha: February 20, 2000

Ama-platelets awaphazanyiswa yi-Celebrex

Iziphumo ezivela ocwaningweni olulawulwa yi-double-blind, randomized, ne-placebo eshicilelwe encwadini ka-February 2000 ye-Journal of Clinical Pharmacology yembula ukuthi i-arthritis ethandwa kakhulu yi- Celebrex (celecoxib) ayiphazamisi umsebenzi weplatelet ngisho nangama-1200 mg / ngosuku.

Umthamo we-1200 mg / ngosuku empeleni izikhathi eziyisithupha eziphakanyisiwe zokunqunywa kwe-Celebrex enqunyelwe ukwelashwa kwe- osteoarthritis.

Kungani lokhu kutholakala kokugcina umsebenzi weplatelet evamile kubaluleke kangaka? Kubalulekile:

Mayelana NeSifundo

Inhloso yocwaningo kwakuwukuqhathanisa imiphumela yezindleko eziphakeme kakhulu ze-Celebrex ekutheni ukwelashwa kwe- naproxen kumaplatelet .

Ngesikhathi sezinsuku ezingu-10, abahlanganyeli bokutadisha banikezwa ngezikhathi ezithile ukulinganisa okuhlukile koku:

Izikhathi zokuphuza zazisetshenziselwa ukukala umsebenzi weplatelet. Ngokuphambene noCelebrex noma i-placebo, i-naproxen yafakazela ukunciphisa ama-platelet aggregation nokwandisa izikhathi zokuphuma kwegazi.

Iqiniso lokuthi i-Celebrex ayizange iphazamise i-platelet aggregation evamile ukuqinisekiswa okwengeziwe kwe-COX-2 ukukhethwa kwezidakamizwa nokuphepha kwayo.

I-osteoarthritis Nezifo Zezinhliziyo

Ngokuvamile i-osteoarthritis nezifo zenhliziyo zenzeka ndawonye kubantu asebekhulile. I-CDC (Izikhungo Zokulawula Nokuvimbela Izifo) inqume ukuthi abantu abadala kwabangu-1 e-United States bane-hypertension futhi abantu abangaba ngu-1 kwabangu-3 abane-hypertension nabo bane-arthritis.

Cishe umuntu oyedwa kwabayisihlanu abangaphezu kweminyaka engama-35 ubudala athatha i- aspirin njengesilinganiso sokuvimbela isifo senhliziyo. Imiphumela yokutadisha ukusekela i-Celebrex njengendlela yokukhetha abantu abanesidingo se-aspirin ephansi.

Izinsiza ezihlobene